Data from two cohorts of patients with colorectal cancer with either ERBB2 amplifications or ERBB2 or ERBB3 mutations showed that treatment with pertuzumab plus trastuzumab had antitumor activity only in ERBB2 amplification. This evidence concerns the gene ERBB2 and colorectal cancer.